Thoracic aortic aneurysm (TAA) is a devastating vascular disease. TAA patients have dilated ascending aorta that eventually ruptures and leads to death. Treatment of TAA is limited to surgery only. The structural and morphological changes localized to the ascending region have intense effect on functioning of the aorta. Recent scientific studies have demonstrated that the underlying cause of TAA is a result of various alterations at the cellular level. Given that there is an absence of a direct pharmacological treatment for TAA, therefore a growing demand to determine the underlying mechanisms of TAA is utmost necessary to elucidate. Till date, a great progress has been made to diagnose and identify the risk factors of TAA, however a better understanding of the mechanisms that trigger the progression is needed in order to develop new therapeutic strategies. The current review compiles the recent highlights about the contributions of cellular mechanisms involved in the development of TAA.
Introduction
Aorta is the main artery carrying blood from the heart to the different organs of the body. The region of aorta that is closest to the heart is the ascending aorta present in the thoracic cavity ( Figure 1 ). The nature of the tissue present in the ascending aorta is unique and making it prone to many pathological consequences. This region is subjected to aortic dilation, elastin fragmentation, dissection and rupture, ulcer formation or erosion of the vascular tissue and thrombus formation [1] [2] [3] . The triggering step for initiating these pathological conditions in the ascending aorta is not clearly defined. Around 45,000-47,000 deaths are reported every year from aortic diseases in United States alone and the incidence rate has increased over the decades [4 5 ]. This number may vary as many cases are undiagnosed and mistakenly classified as cardiac arrest.
[4] The presence of ascending aorta in the thoracic cavity classifies this pathology as thoracic aortic aneurysms (TAA) (Figure 1 ). Many TAAs are asymptomatic and can occur at any age in both genders. So far the current treatment is limited to surgery [6] [7] [8] . Though with help of modern technology, less invasive clinical methods exist but are at their infant stages. Therefore, persistent needs are required to identify the elements that predispose to the disease and prevent the treatment from surgery to other alternative medicines. The current research is aimed at alternative medical interventions that can improve the damaged regions and restore vascularization of the aorta. To make this change, there is an immeasurable need to define the mechanisms involved in the development of TAA.
Diagnosis and Risk Factors of TAA
TAA is generally detected during regular medical tests including chest X-ray and ultrasound of the thoracic cavity. The physician may further recommend for echocardiogram or computerized tomography or magnetic resonance angiography to further validate and detect the exact location of the damage in the tissue. The later imaging techniques can detect the size and diameter of the aortic dilation. The range of the normal diameter of the ascending aorta is between 3-5-3.9 and if it expands more than 4 cm is considered as aneurysm and it can expand to 5.5 cm in diameter [9] .
There have been various risk factors associated with TAA including age, hypertension, inflammation, smoking, atherosclerosis, dyslipidemia and age of the ascending aorta. The angle of bending of the ascending aorta has been also shown to be another risk factor for TAA [10] . Strenuous exercise or any kind of distress in the chest cavity or an injury during surgeries can also lead to the damage of the ascending aorta and causing TAA. 
Characterization of TAA
TAA is a life-threatening disorder that has a huge impact on the lifestyle of an individual once being diagnosed. TAA is a complex and heterogeneous in nature that is localized to the ascending aortic region mainly but rare cases are also seen in the descending aorta ( Figure 1 ). In general, ascending aorta is comprised of three main layers: intima, media and the adventitia. All these layers are separated by elastic fibers and laminae. The cellular composition of intimal and medial layers is endothelial and smooth muscle cells, respectively ( Figure 2 ). Adventitia is heterogeneous in composition, having vast array of cells; fibroblasts, macrophages, nerve cells, adipose, immune cells in collagen rich in extracellular matrix ( Figure 2) [26 27]. TAA is characterized by luminal enlargement through the whole of the ascending aorta ( Figure 1 ). TAA is a progressive disease, where the aortic intima and medial layers are torn, which allows the entry of blood cells into the media and causes the split of medial layer and that opens up to the development of another channel known as false lumen. At this stage, medial changes lead to elastin fragmentation and medial thickening that profoundly affects the blood flow in the aorta [28] . Further, this region is prone to rupture in patients with continuous aneurysm expansion and aortic wall weakening. The contribution of each cellular component of the ascending aortic wall in TAA is discussed in the following section.
Cellular mechanisms involved in TAA
Recent scientific studies have improved our understanding of TAA, which holds a promising potential of developing into new therapeutic strategies for treating this pathology. Ascending aorta present in the thoracic cavity consists of Genetic mutation in fibrillin 1 leads to C to G change at 1039 nucleotide position that is susceptible and predisposes to MS, a form of TAA. Fibrillin 1 mutations lead to hardening of the aortic wall, increase in transforming growth factor β1 expression, inflammation, elastin degradation and extracellular matrix upregulation [56]. Fibrillin 2 is primarily expressed during the embryonic phase and is responsible for the development of aorta [59] . Unlike fibrllin 1 -/-mice, the absence of fibrillin 2 has no effect on the development of aortic aneurysm.
Fibulin: Fibulin is one of the primary members of extracellular matrix family. The main function of fibulin is in the structural organization of the aortic wall. Fibulin 5 functions as an important role in the development of lamellar structure by connecting elastin and smooth muscle cells [60] . Studies have shown that mutations in fibulin 4 and 5 are related to aortic aneurysms in humans [61 62 ]. Deficiency of fibulin 4 and 5 in mice has resulted in enlargement of ascending aorta. It has demonstrated that aortic tortuosity, slack skin and disordered elastin fibers [63 64 ]. The other forms of this family are fibulin 1, 2 and 3 that have no consequences on aortic aneurysms.
Other Mediators of TAA
Apart from cellular mechanisms involved in TAA, there are biochemical-signaling pathways that are associated with this etiology. Briefly these are inflammatory, oxidative, extracellular matrix proteins, transforming growth factor-β and angiotensin II signaling pathways. Researchers have also focused on these pathways and its effect on downstream targets. Any variations in the expression of the genes involved in these pathways have been demonstrated to be associated in the development of TAA. In addition, there are other mediators regulating the TAA formation such as mechanical pathways. Sheer wall stress and radial strain on the aortic wall play a very critical role in the blood flow through the aorta. Any malfunctioning of a mechanical signal can implicate on the structure and function of resident cells of the aorta.
Treatment and drugs
Till date, there is no direct pharmacological therapy for treating TAA. However, the results of animal model studies have demonstrated encouraging role of few drugs in treating TAA. Angiotensin II receptor blocker (ARBs) are commonly prescribed to hypertensive patients. In mice model of TAA, fibrillin 1 -/-mice, losartan, an ARB has demonstrated to attenuate diameter of aorta and enhanced the structure of the aorta [56] . Similarly, β-adrenoreceptor blocker also showed similar results as of ARB. Another assuring inhibitor is doxycyclin, a matrix metalloproteinase (MMP) inhibitor showed in the same model, reduction of extracellular matrix proteins in particular MMP2 and MMP9 [65 66 ]. Finally, Habashi et al also showed that giving a neutralizing antibody against transforming growth factor β1 into a TAA animal model restored the aortic wall structure [56] . Based on these excellent observations in animal model studies, some of these drugs have entered into clinical trails [67 68 ].
Conclusion
TAA is a very complicated disorder with a huge variation among each case. However, past few years of research with the help of modern techniques and technologies has visualized the discovery of many new results that have provided precious information about the pathology of TAA. These findings have laid the foundation in a new direction for the development of novel treatment strategies in treating TAA. However, unceasing research in this field is the need of the hour to elucidate and complete the puzzle of understanding TAA. This knowledge will definitely lead to more pharmacological therapies that are more specific for each individual. In future, there will be more clinical insights for curing TAA. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. 
